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Extracellular matrix proteins of the tenascin family
resemble each other in their domain structure, and also share
functions in modulating cell adhesion and cellular responses
to growth factors. Despite these common features, the 4
vertebrate tenascins exhibit vastly different expression
patterns. Tenascin-R is speciﬁc to the central nervous system.
Tenascin-C is an “oncofetal” protein controlled by many
stimuli (growth factors, cytokines, mechanical stress), but with
restricted occurrence in space and time. In contrast, tenascin-
X is a constituitive component of connective tissues, and its
level is barely affected by external factors. Finally, the
expression of tenascin-W is similar to that of tenascin-C but
even more limited. In accordance with their highly regulated
expression, the promoters of the tenascin-C and -W genes
contain TATA boxes, whereas those of the other 2 tenascins
do not. This article summarizes what is currently known about
the complex transcriptional regulation of the 4 tenascin
genes in development and disease.
Introduction: The Tenascin Gene Family
Tenascins are a family of large, oligomeric, multi-domain
extracellular matrix (ECM) proteins.1 Four genes encoding
tenascin-C (TNC), tenascin-R (TNR), tenascin-X (TNX), and
tenascin-W (TNW) proteins exist in higher vertebrates, and a
single tenascin gene is found in cephalochordates whereas similar
genes and proteins do not seem to exist in other animal phyla.2-4
Tenascins are characterized by their unique domain structure.
Each monomeric unit comprises an N-terminus with heptad
repeats flanked by cysteine residues. This N-terminal oligomeri-
zation region is followed by EGF-like repeats, and a variable
number of fibronectin type III repeats as a result of alternative
mRNA splicing. At the C-terminus, each subunit ends with a
large C-terminal fibrinogen related domain.1 Via their N-termi-
nal oligomerization domain, tenascin subunits form disulfide-
linked homo-trimers (TNR and TNX) or -hexamers
(“hexabrachions;” TNC and TNW). Rather than representing
bona fide structural components of the extracellular matrix, tenas-
cins are “matricellular” proteins4 involved in modifying the inter-
action of cells with extracellular matrix and growth factors, and
hence regulating cell adhesion, migration, growth and differenti-
ation in a context-dependent manner5 (see other articles in this
issue).
A number of earlier reviews have summarized the discovery,6-9
protein structure,1,8 splice variants,10,11 binding partners and cel-
lular receptors,12 expression patterns13 and functions in vitro and
in vivo9,14-17 of the 4 tenascins, and more information on these
topics is to be found in other contributions to this special issue.
The present article has a different and narrow focus, namely to
summarize what is currently known about the regulation of
expression of tenascins. We briefly review the expression patterns
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of the 4 tenascins in development, regeneration and disease, and
focus on the transcriptional regulation of their respective genes
by growth factors and mechanical stimuli. Except for TNX,
which has a widespread distribution like many ECM proteins,
the other 3 tenascins show a very restricted occurrence during
embryogenesis, tissue remodeling and tumor formation.8,9,18,19
Their patterns of localization, which are specific for each of the 4
family members, point to tightly controlled spatial and temporal
expression, and are likely to reflect complex gene regulation. To
date, the promoter of the TNC gene has been studied most exten-
sively in various species, whereas information on the gene pro-
moters of the other 3 family members is still comparatively
sparse. Thus, the apparent imbalance between chapters in this
article reflects the current status of the literature.
Tenascin-C: Expression in Organogenesis,
Inﬂammation, Tissue Repair and Cancer
Structure of the tenascin-C (TNC) gene
Tenascin-C (gene name TNC) is the founding member of the
respective family of ECM proteins.5 The human TNC gene
(gene ID: 3371) is on chromosome 9q33; it contains 29 exons of
which 9 (each coding for a fibronectin type III domain) can be
alternatively spliced.20-22 The transcript starts with a non-coding
exon, separated by an intron >20 kb long, and followed by exon
2, which contains the ATG start codon for translation initiation.
TNC mRNA from human fibroblasts and human melanoma cells
analyzed by primer extension and S1 nuclease showed a single
transcription start site (TSS) localized to the first exon (Fig. 1).
Sequencing of approximatively 2300 bp of the TNC gene 50-
flanking region has revealed several potential binding sites for
transcription factors (see below).20 The sequence of 220 bp
upstream to the TSS was identified as region with high promoter
activity; it contains a classical TATA box at ¡20 to ¡26 bp. A
putative silencer sequence was localized to the fragment between
¡220 and ¡2300 bp.20 Similarly, primer extension analysis of
mRNA isolated from brain tissue of mouse embryos showed a
single TSS that lays 27 bp downstream of the TATA box.23
Moreover, the 230 bp proximal promoter sequence, which is
conserved between species, was found to be highly active in driv-
ing reporter gene expression when transfected into both mouse
and human fibroblasts.23 The chicken TNC (cytotactin) gene fea-
tures a TATA box at a similar position as the mammalian coun-
terparts.24 A comparison between the human, mouse and
chicken TNC promoters has been presented by Jones and Jones
(2000).25
Tenascin-C gene regulation by patterning genes during
development
TNC received much attention after its discovery because of its
highly specific and restricted expression patterns during verte-
brate embryogenesis.26,27 In contrast to many other ECM pro-
teins, TNC often appears in an all-or-none fashion both in space
and time. Specifically, the protein is an early marker of tendon,
ligament and bone formation.26 Other prominent sources are
neural crest cells in early embryos,28 Schwann cell precursors in
developing peripheral nerves,29,30 and vascular smooth muscle
cells around arteries.31 In addition, TNC expression is often asso-
ciated with specific morphogenetic events during organogenesis,
e.g. with the formation of somites, segmental nerves,30 mammary
glands,27,32 teeth,33 kidneys34 and lungs.35 It was therefore an
obvious possibility that the TNC gene could be controlled by seg-
mentation and patterning genes. Indeed, some of the early publi-
cations on TNC promoters from different species investigated
their regulation by homeobox transcription factors (for detailed
information about the location and sequence of cis-acting ele-
ments in the TNC promoter, see Table 1 and Fig. 2). For exam-
ple, the chicken promoter was found to be strongly activated by
co-transfection of fibroblasts with even-skipped homeobox 1
(EVX1), and by mutational analysis, an AP1 element was identi-
fied that was essential for this response.36 The same AP1 site was
found to mediate activation of the promoter by serum growth
factors, and EVX1 overexpression potentiated the effect of serum.
Thus, EVX1 appears to activate the TNC gene indirectly by syn-
ergizing with JUN/FOS transcription factors, which target the
AP1 site.
On the other hand, a homeobox transcription factor involved
in anterior head formation, orthodenticle homolog 2 (OTX2),
was shown to bind directly and with high affinity to the human
TNC promoter and to suppress its transcriptional activity;37,38
the OTX2 target sequence is conserved in the mouse (but not
chicken) gene. Similarly, the POU-homeodomain transcription
factor POU3F2 (also called BRN2 or Oct-7) was demonstrated
to interact directly with a reverse octamer sequence in the mouse
Figure 1. Schematic representation of all tenascin genes. Gene models
of TNC, tenascin-C; TNN, tenascin-W; TNR, tenascin-R; TNXB, tenascin-X
were captured from the NCBI database (http://www.ncbi.nlm.nih.gov/
gene/). TNC, TNN and TNR have a single transcription start site (TSS1)
whereas the TNXB gene has 4 closely clustered TSSs(TSS1–4) in its princi-
ple promoter shown here. Non-coding exons up to the ﬁrst coding exons
(indicated by the translation start codon ATG) as well as the last exons
are numbered with e1, 2, . . . below the models. Note that the TNC and
TNN genes possess TATA boxes (red triangles) whereas the TNR and the
TNXB genes do not.
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Tnc promoter, which is conserved in the human and also the
chicken gene.39
In addition, the proximal promoter of the chicken, mouse and
human TNC gene contains another conserved homeodomain
binding sequence (HBS).25 Paired-related homeobox 1 (PRRX1;
formerly called PRX1 or Mhox), a transcription factor involved
in limb and craniofacial morphogenesis,40 is a marker for perios-
teal cells41 and often co-expressed with TNC. Overexpression of
PRRX1 strongly induced a full-length mouse Tnc promoter con-
struct in a vascular smooth muscle cell line.42 Later, PRRX1 was
demonstrated to trans-activate Tnc gene transcription in mouse
pulmonary endothelial cells through direct interaction with the
HBS located within the proximal promoter.43 Furthermore,
increased deposition of TNC along the arterial wall in pulmonary
vascular lesions of patients with mutated BMP type II receptors
was highly associated with the expression of PRRX1.44
TNC is a prominent early marker for developing tendons.26
The basic helix-loop-helix transcription factor scleraxis (SCX) is
essential for development of load-bearing tendons.45 The Tnc
gene was therefore assumed to be a target gene of this tendon-
specific transcription factor.46 In Scx null mouse embryos, how-
ever, TNC still accumulates in condensing mesenchyme where
tendons normally develop.45 Therefore, the Tnc gene appears to
be controlled by factors that act upstream of SCX during early
tendon morphogenesis, such as PRRX1 (see above).
Tenascin-C gene regulation by mechanical stress
Whereas TNC is expressed transiently in many developing
organs, it persists in the adult mainly in a few structures bearing
high tensile stress, such as tendons, ligaments, and the smooth
muscle walls of arteries.7,25 It was therefore speculated early on
that its gene might be regulated by mechanical forces. Indeed,
TNC expression was found to be induced in vivo e.g., by hyper-
tension in the arterial walls of rats,47 or upon supra-physiologi-
cal loading in skeletal muscle connective tissue of chicken,48
rat49 and human.50 Transduction of external mechanical stimuli
requires integrins as bridges between ECM and the cytoskele-
ton.51 Depending on the precise nature of the stimulus, various
Figure 2. Scheme of the gene promoters of the 4 tenascins. The transcription start sites (TSS) are indicated with blue arrows in front of the ﬁrst exons (e1;
blue boxes). The start codons (ATG) of the translation start sites are marked with red arrows in the second (e2) or third exon (e3; for TNR), respectively.
The upstream promoter sequences are represented by horizontal light blue lines, on which the experimentally conﬁrmed transcription factor binding
sites are marked by vertical bars. Dark blue color refers to those sites reported for the human promoters; sites described so far in the mouse promoters
only are labeled in green. For nomenclature of binding sites and transcription factors, see the list of abbreviations. For additional information and publi-
cations on individual binding sites, refer to Table 1. Note that the promoter sequences are not drawn to scale. However, the exact location of each bind-
ing site is indicated below the bars; numbers refer to the distance in base pairs from the transcription start site.
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integrin-dependent signaling pathways can then be triggered,
such as Ca influx, activation of ERK1/2, NFkB, and RhoA/
ROCK.52 An extensively studied mechanotransduction pathway
concerns the rapid activation of the TNC gene by cyclic strain
(10%, 0.3 Hz for 1–6 h) in chicken and mouse fibroblasts
attached to elastic substrates, which depends on Rho/ROCK
signaling.53 Pericellular fibronectin, integrin a5b154 and integ-
rin-linked kinase (ILK)55 were shown to be required for RhoA
activation and TNC induction in response to cyclic stretch in
mouse fibroblasts. Strain-mediated RhoA activation triggered an
increase in cellular actin assembly,56 which in turn lead to translo-
cation of megakaryoblastic leukemia-1 (MKL1; also called MAL
or MRTF-A) from the cytoplasm to the nucleus,55 where it is
known to act as a trancriptional regulator.57 Accordingly, TNC
induction by cyclic strain was abolished by MKL1 knockdown in
NIH3T3 fibroblasts.58 Furthermore, overexpression of MKL1
induced TNC expression in both fibroblasts58 and mammary epi-
thelial cells.59 MKL1 regulates the transcriptional activity of serum
response factor (SRF).60 Indeed, the mouse Tnc promoter contains
a serum response element (SRE; CArG-box) located 1.4 kb
upstream from the transcription start site, which is in part involved
in its activation. However, Tnc induction by cyclic strain was
found to be independent of SRF but strictly dependent on the
interaction of the SAP domain of MKL1, a putative DNA-bind-
ing domain, with the proximal Tnc promoter.58
Among vascular diseases, hypertension is correlated with ele-
vated TNC abundance around vessels, concomittently with an
increase in wall stress. In human arterial smooth muscle cells,
cyclic strain (13%, 0.5 Hz for 24 h) was found to control the
expression and activity of nuclear factor of activated T cells 5
(NFAT5) in a JNK-dependent manner.61 Once translocated into
the nucleus in response to strain, NFAT5 was able to induce
TNC gene expression. Five NFAT consensus sequences were
found in the first 3512 bp of the human TNC promoter
sequence upstream of the transcription start site, and for the first
of them (at -820 bp), cyclic strain-induced binding was demon-
strated by ChIP analysis.61 Note that the Rho/MKL1 pathway
described above directly activates the mouse Tnc gene within
1–3 hours in response to strain, whereas the JNK/NFAT5 path-
way requires prior synthesis of a transcription factor and takes
24 h for human TNC induction.
Yet a different mechanotransduction pathway was found to be
responsible for TNC induction by cyclic strain in rat cardiomyo-
cytes. It is noteworthy that a similar strain amplitude (9–14%)
but a higher frequency (1 Hz) was used.62 In this case, the
response depended on release of reactive oxygen species and acti-
vation of NFkB. A consensus sequence for this transcription fac-
tor at -210 bp was required for mechanical activation of the rat
Tnc promoter, and shown to bind the p50 subunit of NFkB in
response to strain.62 Moreover, TNC expression is not only regu-
lated by dynamic (cyclic) strain, but also by static tensile stress.
For example, TNC expression by chicken fibroblasts was found
to be high when they were embedded in an attached (stressed)
collagen matrix, but diminished when the matrix was released
from its anchors (relaxed). A conserved region in the the chicken
TNC promoter was required for this response63 (Table 1).
Interestingly, a GAGAC/TC motif was identified in this
region.64 This motif is present in the control regions of other
mechanoresponsive genes where it is recognized by NFkB,65 but
the factors binding to it in the chicken TNC promoter have not
been identified. In any case, these examples show that depending
on the cell type and on the exact mode and dosis of mechanical
stress, the TNC gene appears to be regulated via distinct mecha-
notransduction pathways (Table 1).
Tenascin-C gene regulation by growth factors during tissue
repair
In the adult, TNC protein is restricted to few tissues.7,25,66
However, the protein becomes prominently expressed de novo in
practically every tissue upon inflammation in response to chemi-
cal or mechanical injury, as well as due to other pathological pro-
cesses.1 A number of cytokines has been shown to induce TNC
expression in different cell types, among them pro-inflammatory
(IL-1a67 and IL-1b68) as well as anti-inflammatory (IL-469 and
IL-1370). Cytokines signal via various intracellular pathways
(JAK/STAT, MAPK, NF-kB71,72). However, there are no direct
functional studies so far on the control of TNC promoter activity
by cytokines.
More is known about TNC gene regulation during wound
repair. Transforming growth factor-b (TGF-b) plays an impor-
tant role as inducer of extracellular matrix protein expression dur-
ing development and in tissue regeneration.73,74 Stimulation of
TNC synthesis has been detected after treatment of chicken
embryo fibroblasts with TGF-b1.75 A direct role of TGF-b in
promoting TNC expression was observed in mammary epithelial
cells (HC11) and in mouse embryo fibroblasts.76 For astrocytes,
it was shown that the expression of TNC is controlled by the
canonical SMAD-mediated TGF-b signaling pathway and by
fibroblast growth factor (FGF).77 Series of 50-deletions of the
human TNC promoter revealed the presence of 2 potential
SMAD2/3 binding sites in the proximal promoter region78
(Table 1 and Fig. 2). In addition, it was shown that SMADs
interact with co-factors such as SP1 or ETS1 in a complex with
CBP/p300, which possess binding sites located within the same
promoter region, in order to achieve proper TNC gene transcrip-
tion induced by TGF-b in human dermal fibroblasts78 (Table 1
and Fig. 2).
In the same cells, platelet-derived growth factor (PDGF) regu-
lates TNC gene expression via PI3K/AKT signaling, which trig-
gers the interaction of transcription factors SP1 and ETS1/ETS2
in an active complex that recognizes ETS binding sites (EBS) in
the promoter79 (Table 1 and Fig. 2).
In chicken embryo fibroblasts, PDGF and TGF-b growth
factors were shown to act in an additive manner with tensile
strain in promoting TNC mRNA expression,53 and thus an
increase in these factors might indirectly stimulate TNC pro-
duction in response to mechanical load. For example, TNC
accumulates in angiotensin II- induced perivascular fibrotic
lesions in hypertensive mice. Angiotensin II was shown to trig-
ger aldosterone-induced inflammation, which indirectly stimu-
lated TNC expression by upregulating PDGF-A/B, PDGF
receptor-a, and TGF-b1 in this model.80
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Glucocorticoids are potent anti-inflammatory steroid hor-
mones. They function by binding to nuclear receptors that act as
transcription factors, but can also negatively regulate gene expres-
sion by inhibiting the activity of other factors like AP1 and
NFkB.81 Glucocorticoids have also been described as important
hormones involved in myelopoiesis, and they can directly act at
the progenitor cell level or by modifying the expression of ECM
components. Down-regulation of TNC expression by glucocorti-
coids was shown in bone marrow stromal cells.82 These authors
suggested that the different TNC distribution between bone mar-
row of newborn and adult mice controlled by glucocorticoids
might in part influence the hematopoiesis process. Putative bind-
ing sites for glucocorticoid receptors have been identified in the
chicken TNC promoter sequence,63 but their function in the hor-
mone response has not been explored. A further repressor motif
was mapped in the human TNC promoter and was demonstrated
to bind GATA6, a zinc finger transcription factor known to regu-
late the synthetic phenotype of vascular smooth muscle cells.
Exogenous expression of GATA6 in dermal fibroblasts negatively
modulated the level of TNC protein, and inhibited its induction
by IL-4 and TGF-b83 (Table 1).
Tenascin-C gene regulation in cancer
Ets binding sites within the TNC promoter are not only
important for its activation by the PDGF/PI3K/Akt pathway
(see above), but were also shown to be the targets of EWS-ETS
transcription factor. EWS-ETS is a chimeric gene found in sev-
eral tumor types such as Ewing sarcoma and peripheral primitive
neuroectodermal tumors.84 In a similar setting, oncogenic trans-
formation of primary rat embryonic fibroblasts can be the conse-
quence of the activity of transcription factor c-Jun in cooperation
with an activated Ras gene.85 The transient expression of TNC
induced by c-JUN could facilitate the de-adhesion of fibroblasts
from the extracellular matrix, thus promoting their transforma-
tion. The c-JUN transcription factor contains a bipartite DNA
binding domain which recognizes GCN4/AP1 and NFkB bind-
ing sequences, located in the human TNC promoter region85
(see Table 1 and Fig. 2).
SOX4 is a transcription factor overexpressed in many human
tumors, and TNC was identified as a direct SOX4 target gene.86
TGF-b is also associated with the enrichment of TNC protein in
the stroma of malignant breast tumors.87,88 Through gene set
enrichment analysis it was found that direct target genes of TGF-
b–activated SMAD3 were also enriched in the list of the SOX4 tar-
get genes. In the context of malignancies, this would suggest a coop-
eration between SOX4 and TGF-b1 in controlling TNC expression.
In addition to SOX4, other patterning genes might be
involved in TNC accumulation during malignancy in a cell- and
tissue-specific manner. For example, overexpression of POU3F2
(Brn2; see 2.2.) stimulated transcription from the Tnc promoter
in a neuroblastoma cell line, but had no effect in glioma cells.39
Interestingly, PRRX1, shown to induce TNC in vascular smooth
muscle cells (see 2.2) was identified as an important inducer of
mesenchymal-epithelial transition both in the embryo as well as
in cancer cells.89 Thus, PRRX1 might also play a role in TNC
induction in tumors to facilitate local invasion.
Notch is a large transmembrane protein that acts as receptor
for cell-bound ligands Delta and Jagged; upon activation, its
intracellular domain is cleaved and translocates to the nucleus
where it acts as transcriptional regulator through binding to
RBPJk/CSL.90 High levels of Delta-like-1 and Jagged-1 ligands
expressed in many glioma cell lines and primary human gliomas
were shown to be important for the induction of the Notch sig-
naling pathway.91 The proximal promoter of the human TNC
gene includes an RBPJk/CSL binding sequence responsible for
Notch2-mediated trans-activation in glioblastomas, and is likely
to mediate strong TNC induction in these tumors.92 Conversely,
in lung metastases of breast cancer, TNC accumulation has been
implicated in supporting the Notch signaling pathway.93 Taking
the 2 findings together, there may be a positive feedback between
Notch and TNC expression, which in turn will further amplify
the Notch signaling pathway.
Posttranscriptional regulation of tenascin-C gene
by microRNAs
The role of microRNAs as regulators of post-transcriptional
gene silencing is well documented,94,95 and recent studies have
shown that the repression of certain microRNAs corresponds to a
more pronounced tumorigenesis.96 For example, downregulation
of SOX4 and TNC is controlled by miR-335, and loss of this
microRNA in breast cancer was shown to induce metastasis in
part by increased TNC levels.97 Other findings show how TNC
promotes oncosphere formation by a metastasis-initiating breast
cancer cell population for lung colonization, and in this context,
GATA3 and miR-335 were downregulated.93
Tenascin-R: An ECM Protein Mainly Restricted
to the Central Nervous System
Structure of the tenascin-R (TNR) gene
The human TNR gene (gene ID: 7143) is located on chromo-
some 1q24 and contains 23 exons. The transcript starts with 2
non-coding exons, separated by large introns from exon 3 which
contains the ATG start codon98,99 (Fig. 1). The non-coding part
of the tenascin-R gene spans a much larger region than the region
of the protein encoding exons (Fig. 1). As demonstrated by S1
nuclease analysis, TNR transcripts of fetal, adult, and neoplastic
human brain all contained both exons 1 and 2, indicating the
presence of a single TSS at exon 1.99 The proximal promoter
region is not recognizable as such and lacks a TATA box, CAAT
box, GC-rich regions, or an initiator element, but potential bind-
ing sites for GATA1/2, MyoD, glucocorticoid receptor and
homeobox binding sites were present in the region of ¡111 to
-974bp. A non-typical TATA box, multiple GAGA boxes and an
initiator-like element were identified within exon 1.99 However,
inclusion of exon 1 did not play any role in the transcriptional
activation directed by a 230 bp promoter construct and a short
57bp promoter construct was sufficient for full and cell type-spe-
cific activity of the human TNR promoter in cell culture99
(Table 1 and Fig. 2). The gene and promoter structure is highly
conserved also in the rat100 and the mouse101. The TATA-less
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mouse TNR promoter displays canonical binding sites for poten-
tial regulators such as GATA-1/2, AP1 and p53 transcription fac-
tors as well as glucocorticoid receptors.101 However, all these
binding sites are outside the 167bp short promoter region and
exon 1 shown to be sufficient for the induction of transcription
in cells of neuronal origin101 (Table 1 and Fig. 2).
Expression of tenascin-R in neural development, injury
and cancer
TNR, originally designated as janusin in rodents and restrictin
in chicken, is almost exclusively located to the central nervous
system,102-105 but transiently appears also in Schwann cells dur-
ing peripheral nerve development.106 Previous work has shown
that 2 TNR splice variants of 160 and 180 kDa are expressed in
the central nervous system by oligodendrocytes and a few neuro-
nal cell types, but not by astrocytes or fibroblasts.107 In the devel-
oping human cortex, the spatiotemporal distribution of TNR
parallels neuronal migration.108 In vitro experiments have dem-
onstrated that TNR promotes adhesion and differentiation of oli-
godendrocytes and astrocytes by binding to sulfatides on cell
surfaces.105,109 Conversely, TNR can inhibit neurite outgrowth
either by interacting with adhesion molecule contactin 1 (F3/
F11) or by interfering with integrin-dependent adhesion to fibro-
nectin (reviewed in Pesheva et al., 2000110 ).
In a pathological context, activation of microglial cells after
facial nerve axotomy in rats has been shown to downregulate
TNR protein expression with the subsequent loss of its anti-adhe-
sive properties.111 On the other hand, TNR is up-regulated in
the injured visual pathway of the lizard that has the capacity to
regenerate.112 In brain cancer, TNR was reported to be overex-
pressed in pilocytic astrocytoma, oligodendroglioma and ganglio-
glioma, but not glioblastoma.113
Tenascin-R gene regulation by growth factors
In mice, oligodendrocyte precursor cells synthesize most
tenascin-R, whereas expression decreases with differentiation. In
more mature oligodendrocytes, expression of TNR was stimu-
lated by coculture with astrocytes or neurons, and was also
induced by adding platelet-derived growth factor (PDGF) but
not basic fibroblast growth factor.114 Rat pheochromocytoma
cells (PC12) express high levels of Tnr mRNA after nerve growth
factor (NGF) treatment.102,114 In contrast, rat oligodendrocytes
treated with conditioned medium from activated microglia show
a reduced Tnr mRNA expression due to the release of injury fac-
tors such as TNF-a.111 Unfortunately, there are no studies yet
how these growth factors and cytokines regulate the TNR gene
on the promoter level.
Tenascin-X: A Regulatory Component of Collagen
Fibers
Structure of the tenascin-X (TNXB) gene
The human TNX gene was discovered as unknown “gene X”
present in the major histocompatibility locus III (MHCIII).115
There, it is found on the opposite strand of the CYP21A2 gene
and partially overlaps with it.116,117 CYP21A2 encodes steroid
21-hydroxylase, and mutations in this gene cause congenital
adrenal hyperplasia. However, a fraction of cases with deletions
in this genomic region are also deficient for TNX; these patients
suffer in addition from hyperextensible skin and joint laxity typi-
cal of Ehlers-Danlos syndrome.116,118,119 The MHCIII gene
locus is very complex and has been partly duplicated resulting in
2 TNX gene copies TNXA and TNXB, of which TNXA is a trun-
cated version.120,121 In the human genome TNXB (gene ID:
7148), the gene coding for the intact TNX protein, is located on
chromosome 6p21.3; it counts 38 exons and transcription can
take place from 3 different widely separated promoters.120 How-
ever, only one of the 3 promoters was shown to be the main con-
trol region for TNXB transcription in all tissues tested and has
thus been analyzed in more detail120,121 (Table 1 and Fig. 2).
This main TNXB promoter is depicted in Figure 2. It lacks
TATA or CAAT boxes and drives transcription form 4 closely
clustered TSSs distributed over 194bp in the region of the first
non-translated exon.120,121 More recently, yet another promoter
and TSS within the TNXB gene was described.122 This promoter
was shown to be activated by hypoxia resulting in a transcript
encoding a truncated short TNXB protein with cytoplasmic
localization. The transcripts were mainly found in the adrenal
gland.122 Little is known about a possible intracellular function
of this truncated TNXB, except that it was found to interact with
the mitotic motor kinesin Eg5.123 Analysis of the main promoter
of the full length TNXB gene revealed several putative binding
sites for Sp1/Sp3 transcription factors, of which a cluster of 5
sites close to the TSSs were proven to be functional and required
for driving TNXB expression in fibroblasts.121 The same gene
organization was found for mouse Tnxb, with a non-coding first
exon, a TATA-less promoter and an Sp1 site 145 bp upstream of
the major transcription start site with a critical role in transcrip-
tion of this gene124 (Table 1 and Fig. 2).
Expression of tenascin-X in collagen-rich tissues
As mentioned above, mutations or deletions in the human
TNXB gene cause Ehlers Danlos syndrome,118 and certain
TNXB mutations are reported to cause another connective tissue
disorder, vesicouretral reflux.125 Deletion of the Tnxb gene in
mice was subsequently shown to phenocopy the connective tissue
defects observed in affected human patients.126 Thus, in apparent
contrast to the other tenascins, TNX protein has a clear structural
role in connective tissue integrity. It is reported to (indirectly)
bind to and bridge collagen fibrils127,128 and regulates collagen
deposition in vivo.127-129 During rat embryonic development,
Tnxb mRNA is especially prominent in the epicardium, skeletal
muscle connective tissue, and tendon primordia.130 In the adult
pig, TNXB mRNA becomes widely and constituitively expressed
in most connective tissues, but is present at higher levels in ten-
dons, ligaments, and perineural sheaths.131 Despite of consider-
able overlap on the tissue level especially in the embryo, on a
smaller scale the distribution of mouse Tnxb mRNA and TNX
protein was found to be distinct and often reciprocal to that of
TNC.18 Also strikingly different from tenascin-C, there is so far
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no report indicating an induction of tenascin-X expression in
inflammation or wound healing.
Tenascin-X gene regulation by growth factors and hormones
Unlike for the other proteins belonging to the tenascin family,
there are so far no reports indicating that TNX is regulated by
growth factors or cytokines. Thus, the signaling pathways that
act on the Sp1/Sp3 sites described above in the TNX promoter
are at present unknown. Like TNC and TNW, however, TNX is
subjected to negative regulation by glucocorticoids,132 but again
the mechanism has not been elucidated yet on the gene promoter
level.
Tenascin-X gene regulation in cancer
Not only during embryogenesis, but also in the context of
malignancy TNX appears to be regulated in an opposite way
compared to TNC. For example, TNX expression is prominent
in normal pig skin but strongly suppressed in cutaneous mela-
noma, where TNC is highly upregulated.133 In contrast to TNC,
TNX is not induced in breast and ovarian carcinomas, but has
been reported to be a marker for malignant mesothelioma.134
Tenascin-W: Expression in Osteogenesis
and Tumorigenesis
Structure of the tenascin-W (TNN) gene
The first tenascin-W gene to be discovered and cloned was
from zebrafish and named tnw.135 Unfortunately, its mouse
ortholog136 was subsequently called tenascin-N;137 Tnn for the
mouse and TNN for the human are now the official gene names
in the NCBI data base. The complete characterization of the
human TNN gene (ID: 63923; chromosome 1q23-q24) was car-
ried out in 2007.138 The human TNN gene consists of a total of
19 exons spanning 80 kb of genomic DNA and the transcript
starts with a non-coding exon (Fig. 1). The same gene organiza-
tion is found for mouse Tnn, except for presence of 3 additional
exons encoding 3 additional fibronectin type III repeats.139 Thus
the mouse TNW protein is about 30kDa larger than the human
counterpart. The first non-coding exons as well as about 600bp
5` of the transcription start are highly conserved between human
and mouse orthologs indicating the presence of conserved pro-
moters, as revealed by the conservation tracks of the UCSC
genome browser (http://genome.ucsc.edu/). Using ConSite
(http://consite.genereg.net/) to explore transcription factor bind-
ing sites shared by the putative human and mouse promoter
sequences revealed a conserved TATA box as well as conserved
SMAD binding elements. However, the relevance of these sites
and the functionality of the TNN promoter still need to be tested
experimentally.
Expression of tenascin-W in bone formation and cancer
TNC and TNW proteins show partially overlapping expres-
sion patterns in the developing and adult skeleton.140 Most of
the research based on the regulation of TNW expression in a
physiological context indicates its significant role in
osteogenesis.9 For instance, addition of TNW to explant cultures
of frontal bones increased their growth, suggesting that TNW
can accelerate bone formation in a complex multicellular envi-
ronment.141 Furthermore, in a transgenic mouse model, overex-
pression of GFP under a Prrx1 promoter was used to isolate
osteochondro-progenitor cells from the periosteum.41 These cells
expressed high levels of TNW protein, proving its association
with PRRX1-positive bone progenitor cells. Thus, it is tempting
to speculate that similarly to TNC, TNW might be regulated by
PRRX1. In the adult organisms, TNW is predominantly
expressed in the periosteum as well as in other stem cell niches
similar to TNC.142
In tumors, TNW is again similarly distributed as TNC and
high amounts are present in cancer stroma of most solid
tumors.76,138,143 However, in comparison to TNC, TNW repre-
sents an even more specific tumor marker in several malignancies
such as in kidney, lung and colon cancers.19,143 In brain cancers
TNW was found to be specifically expressed in blood vessels, and
in vitro studies showed pro-angiogenic activity of TNW added to
endothelial cell cultures.144 Also in kidney and lung cancer, a
strong association of TNW expression was found with tumor
blood vessels.19 These studies support the potential of TNW as a
tumor biomarker. Its strict association with blood vessels suggests
a good accessibility from the blood stream for antibody-drug-
conjugate based therapeutic strategies.
Tenascin-W gene regulation by growth factors
Bone morphogenetic protein 2 (BMP2) is able to induce
TNW expression in periosteum during endochondral bone for-
mation in mice.145 An in vitro osteogenesis model using the
mouse bone marrow-derived Kusa-A1 cell line shows an increase
of Tnn transcript starting with differentiation into osteoblasts.146
Similarly, mouse C2C12 myoblasts differentiate into osteoblastic
cells upon treatment with BMP2 and concomitantly express
TNW.136 The induction of TNW synthesis by BMP2 in mouse
E14.5 primary embryo fibroblasts as well as in mouse HC11
mammary epithelial cells occurs via the non-canonical p38
MAPK signaling pathway.76 TNW was also strongly induced by
BMP7 in embryonic cranial fibroblasts in vitro.147 Among other
regulators of bone formation, WNT5a signaling is indirectly
involved in promoting TNW expression through p38 activation
of an unknown TNW inducer, thus controlling bone density.148
Many factors involved in the regulation of TNW expression in
bone formation are also present in cancer tissues and may be
responsible for the cancer-specific expression of TNW.
Conclusions and Outlook
The four members of the vertebrate tenascin family are quite
similar not only in their overall domain organization, but as typi-
cal “matricellular” proteins also appear to fulfill similar functions:
There is increasing evidence that they all modulate cell adhesion
and cellular responses to growth factors and cytokines in a con-
text-dependent manner.1 In view of these structural and func-
tional similarities, it is surprising that the 4 tenascins exhibit
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vastly different expression patterns in space and time. TNR is
almost exclusively found in the central nervous system and its
expression level is affected by just a few known growth factors. In
contrast, TNC is an “oncofetal” or “stress” protein that is con-
trolled by many stimuli and can appear in almost any tissue and
cell type in the embryo and the adult, however just at certain
times and in specific locations. TNX is a constitutive component
of most connective tissues and its level is barely influenced by
growth factors, whereas the expression of TNW is again more
similar to that of TNC, although it is even more restricted to
developing/remodeling bone, certain stem cell niches,66 and to a
subset of tumors. These observations point to very distinct mech-
anisms of regulation for the various family members. Fitting with
a highly regulated versus a more constitutive expression, respec-
tively, the gene promoters of TNC and TNN have classical
TATA boxes ca. 20–40 bp upstream of their transcription start
sites, whereas the promoters of TNR and TNXB are TATA-less.
TNC and TNR genes have a first untranslated exon separated
from the second ATG-containing exon by a very large intron,
which is likely to be involved in gene regulation. TNR has 2
untranslated exons and the ATG translation start site is found in
the third, whereas TNXB even possesses 3 alternative promoters
and non-coding first exons that are subjected to alternative splic-
ing (see above).
Because the TNC gene was the first of the family to be charac-
terized, most is known about its regulation, although it turns out
to be overwhelmingly complex. The responsiveness of the TNC
gene to segmentation genes, growth factors/cytokines and
mechanical stress appears to be very similar in different vertebrate
species, which is reflected in the high sequence similarity in parts
of the promoter regions. Nevertheless, although many of the
same cis-acting regulatory elements have been identified in the
chicken, mouse and human TNC promoter, there appear to be
differences in their arrangement and activity.25 Although TNW
is quite distantly related to TNC within this protein family, its
expression pattern and the regulation of its gene TNN appears to
be most similar to that of TNC, especially also in stem cell
niches142 and in cancer. Future research is likely to reveal more
about similarities and differences in the control of these 2 genes
e.g. by TGF-bs vs. BMPs, or by various cytokines. Conversely,
TNR is the closest family member of TNC on the protein level,
but it is regulated completely differently. It is remarkable that
only about 200 bp of the proximal promoter and sequences in
the first exon of the TNR gene are necessary and sufficient for its
expression exclusively in neuronal cells.101 Thus, this gene
appears to represent a relatively simple case of tissue-specific
regulation, and it will be interesting to work out the exact mecha-
nism. As for TNX, it exhibits a constitutive expression more like
TNR, but in a reciprocal fashion since it is found in most tissues
except the CNS. Nothing is known yet about the mechanism for
tissue-specific expression of the TNXB gene, and the lack of regu-
lation by growth factors and the relative scarcity of putative cis-
acting elements in its promoter are noteworthy.121 For more
meaningful comparisons between the genes of this family, it
would be important to learn more about the regulation of TNR,
TNXB and TNWN genes in the future. In the case of TNC, sys-
tems biology and computational approaches will probably be
required to fully understand how a dozen or more signaling path-
ways converge to control its very complex gene promoter.
Why is it relevant to study the regulation of tenascins in even
more detail? TNR and TNX, because of their largely constitutive
expression, might perhaps be less interesting in this respect. Of
course, TNX will remain in focus because of its important func-
tion in tissue integrity and its association with human disease,
and TNR might be further investigated as a prime example for
highly tissue and cell type-specific gene regulation. In case of the
highly regulated TNC and TNW, however, more and more evi-
dence suggests that these 2 proteins are important modulators of
cell division, migration and differentiation in adult stem cell
niches66 as well as in cancer.149 Moreover, because of their very
localized and high expression in the extracellular matrix, both
TNC and TNR are very well suited for targeting antibodies and
drugs to certain types of tumors.150 For this therapeutic approach
to work effectively, it is important to know how TNC or TNW
gene expression is affected e.g., by cytotoxic drugs in combined
therapy, and what signaling pathways are involved. From a basic
research point of view, the tenascins provide an intriguing exam-
ple for a vertebrate protein family of paralogs with similar struc-
ture and function, but with distinct expression patterns in space
and time that are generated by different mechanisms of regula-
tion of the respective genes.
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